Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
1,622
Views
19
CrossRef citations to date
0
Altmetric
Letters to the Editor

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Heinz LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Correspondence[email protected]
,
Meletios A. DimopoulosSchool of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
,
Philippe MoreauUniversity of Nantes, Nantes, France;
,
Wee-Joo ChngNational University Cancer Institute, Singapore; ;National University Health System, Singapore; ;Cancer Science Institute, Singapore; ;National University of Singapore, Singapore;
,
Hartmut GoldschmidtHeidelberg Medical University, Heidelberg, Germany;
,
Roman HájekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
,
Thierry FaconCHRU Lille Hôpital Claude Huriez, Lille, France;
,
Ludek PourUniversity Hospital Brno, Brno, Czech Republic;
,
Ruben NiesvizkyWeill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA;
,
Albert OriolInstitut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;
,
Laura RosiñolHospital Clínic de Barcelona, Barcelona, Spain;
,
Aleksandr SuvorovFirst Republican Clinical Hospital of Udmurtia, Izhevsk, Russia;
,
Gianluca GaidanoDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy;
,
Tomas PikaUniversity Hospital Olomouc, Olomouc, Czech Republic;
,
Katja WeiselUniversitatsklinikum Tubingen, Tubingen, Germany;
,
Vesselina Goranova-MarinovaUniversity Multiprofile Hospital for Active Treatment “Sv. Georgi” and Medical University, Plovdiv, Bulgaria;
,
Antonio PalumboUniversity of Torino, Torino, Italy;
,
Heidi H. GillenwaterOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
,
Nehal MohamedOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
,
Sanjay AggarwalOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
,
Shibao FengOnyx Pharmaceuticals, Inc, an Amgen subsidiary, South San Francisco, CA, USA;
&
Douglas JoshuaRoyal Prince Alfred Hospital, Camperdown, New South Wales, Australia
 show all
Pages 2501-2504 | Received 26 Sep 2016, Accepted 15 Feb 2017, Published online: 17 Mar 2017

References

  • Johnson TM. Multiple myeloma treatment and management in the elderly. Consult Pharm. 2014;29:434–438, 440–444, 446–451.
  • Palumbo A, Magarotto V. Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res. 2011;1:190–204.
  • Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1:18–24.
  • Vestal RE. Aging and pharmacology. Cancer. 1997;80:1302–1310.
  • John V, Mashru S, Lichtman S. Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging. 2003;20:737–759.
  • Yancik R, Ganz PA, Varricchio CG, et al. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19:1147–1151.
  • Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636–4642.
  • McBride A, Klaus JO, Stockerl-Goldstein K. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am J Health Syst Pharm. 2015;72:353–360.
  • Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
  • Palumbo A, Stewart AK, Rajkumar SV, et al. Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients (pts) with relapsed multiple myeloma (RMM) based on age: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). Clin Lymphoma Myeloma Leukemia. 2015;15:e75–e76.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.